Código QR (código de barras bidimensional)

Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

ABSTRACT Background Gemcitabine plus cisplatin (GC) has been the global standard for advanced biliary tract cancer (BTC). The triplet regimen gemcitabine–cisplatin–S‐1 (GCS) demonstrated superiority in the MITSUBA trial, but its real‐world effectiveness remains unclear. We compared survival outcomes...

ver descrição completa

Na minha lista:
Principais autores: Hisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Rie Sugimoto, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato, Toru Ishikawa, Takanori Morikawa, Jun Hanaoka, Haruki Mori, Hidenori Toyoda, Tsuyoshi Sanuki, Misaki Yokoi, Hiroyuki Shibata, Koji Fukuda, Kazuhito Kawata, Koji Amaya, Takashi Ito, Masaaki Hidaka, Atsushi Naganuma, Keishi Sugimachi, Satoshi Toshiyama, Makoto Yamasaki, Masaki Kaibori
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2026-07-01
coleção:Annals of Gastroenterological Surgery
Assuntos:
biliary tract neoplasms
cholangiocarcinoma
cisplatin
gemcitabine
Tegafur Gimeracil Oteracil potassium (S‐1)
Acesso em linha:https://doi.org/10.1002/ags3.70202
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados